Avacta Therapeutics to Present at Major Healthcare Conference
LONDON and PHILADELPHIA — Avacta Therapeutics (LSE: AVCT), a pioneering life sciences company specializing in the development of advanced peptide drug conjugates (PDC) aimed at delivering powerful anti-cancer agents directly to tumors, is excited to announce its upcoming presentation at an important global healthcare event in Miami. This noteworthy presentation is scheduled for Wednesday, March 12, featuring significant insights into the company’s innovative strategies and technologies.
Presentation Details
The company will showcase its groundbreaking approaches to cancer treatment, particularly emphasizing its proprietary pre|CISION® platform. This innovative system leverages tumor-specific prodrug techniques to enhance the efficacy of treatments while minimizing damage to surrounding healthy tissues. Stakeholders and industry professionals will gain an in-depth understanding of how Avacta is positioning itself at the forefront of cancer therapy development.
Insights from the Presentation
The live presentation will provide a unique opportunity for attendees to engage with Avacta’s leadership team. The webcast will be accessible via the investors section on the company's official website, with an archive available for at least 30 days thereafter for those unable to attend the live event.
About Avacta Therapeutics
Avacta Therapeutics is committed to innovating cancer therapies through its cutting-edge pre|CISION® technology. This platform focuses on increasing the precision of cancer treatments by targeting the tumor microenvironment. By specifically targeting fibroblast activation protein (FAP), the pre|CISION® approach allows for a controlled release of potent therapeutic agents. This not only increases the effectiveness of treatments but also significantly reduces side effects, paving the way for improved patient experiences.
Contact Information
For more details about Avacta and its promising developments, please reach out through the dedicated contact points:
- Investor Contact: Renee Leck, THRUST Strategic Communications - renee@thrustsc.com
- Media Inquiries: Carly Scaduto Consulting - Carly@carlyscadutoconsulting.com
- General Contact: avacta@icrhealthcare.com
About the pre|CISION® Platform
The pre|CISION® platform stands out in the field of oncology for its ability to concentrate potent anticancer payloads within the tumor microenvironment while protecting normal cells. It has successfully demonstrated its efficacy by cleaving the peptide drug conjugates in tumors, enhancing the specificity of the treatments. As a result, patients can potentially experience better outcomes with optimized dosing and reduced systemic toxicity.
Frequently Asked Questions
What is the purpose of Avacta Therapeutics' presentation?
The presentation aims to highlight innovations in cancer treatments using the pre|CISION® platform, focusing on advanced peptide drug conjugates.
Where can I find the live webcast of the presentation?
The live webcast will be available on Avacta's investor website, with recordings accessible for 30 days post-event.
What does the pre|CISION® platform do?
The pre|CISION® platform enhances anticancer therapies by concentrating drug payloads specifically within tumors, minimizing damage to healthy tissues.
Who should attend the presentation?
Investors, healthcare professionals, and anyone interested in the latest advancements in cancer treatment should attend.
How can I get in touch with Avacta Therapeutics?
Contact can be made through their official email addresses listed on their website or through specified marketing communications specialists.
